Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

PURPOSE: Patients with EGFR-mutant lung adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) after a median of 10–16 months. In half of these cases a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Oxnard, Geoffrey R., Arcila, Maria E., Sima, Camelia S., Riely, Gregory J., Chmielecki, Juliann, Kris, Mark G., Pao, William, Ladanyi, Marc, Miller, Vincent A.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3060283/
https://ncbi.nlm.nih.gov/pubmed/21135146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2692
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires